Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in von Hippel–Lindau patients by MANDILI, GIORGIA et al.
This full text was downloaded from iris - AperTO: https://iris.unito.it/
iris - AperTO
University of Turin’s Institutional Research Information System and Open Access Institutional Repository
This is the author's final version of the contribution published as:
Mandili, Giorgia; Notarpietro, Agata; Khadjavi, Amina; Allasia, Marco;
Battaglia, Antonino; Lucatello, Barbara; Frea, Bruno; Turrini, Francesco;
Novelli, Francesco; Giribaldi, Giuliana; Destefanis, Paolo.
Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal
cancer in von Hippel–Lindau patients. BIOMARKERS. None pp: 1-8.
DOI: 10.1080/1354750X.2016.1269132
The publisher's version is available at:
https://www.tandfonline.com/doi/full/10.1080/1354750X.2016.1269132
When citing, please refer to the published version.
Link to this full text:
http://hdl.handle.net/2318/1621432
For Peer Review Only
 
 
 
 
 
 
Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary 
markers of renal cancer in Von Hippel-Lindau patients 
 
 
Journal: Biomarkers 
Manuscript ID TBMK-2016-0216.R2 
Manuscript Type: Original paper 
Date Submitted by the Author: n/a 
Complete List of Authors: Mandili, Giorgia; Universita degli Studi di Torino, Biotecnologie molecolari e 
Scienze per la Salute 
Notarpietro, Agata; Department of Oncology, University of Turin Medical 
School, Turin, Italy  
Khadjavi, Amina; Department of Surgical Sciences, University of Turin 
Medical School, Turin, Italy  
Allasia, Marco; Department of Urology, Azienda Ospedaliera Città della 
Salute e Della Scienza di Torino – Molinette, Turin, Italy 
Battaglia, Antonino; Department of Urology, Azienda Ospedaliera Città 
della Salute e Della Scienza di Torino – Molinette, Turin, Italy 
Lucatello, Barbara; Department of Endocrinology, Diabetology 
and  Metabolism, Azienda Ospedaliera Città della Salute e Della Scienza di 
Torino –  Molinette, Turin, Italy 
Frea, Bruno; Department of Urology, Azienda Ospedaliera Città della Salute 
e Della Scienza di Torino – Molinette, Turin, Italy 
Turrini, Francesco; Department of Oncology, University of Turin Medical 
School, Turin, Italy  
Novelli, Francesco; Department of Molecular Biotechnology and Health 
Sciences, Molecular Biotechnology Center, University of Turin Medical 
School, Turin, Italy ; Center for Experimental Research and Medical Studies 
(CeRMS), Città della Salute e della Scienza, Ospedale San Giovanni 
Battista, Turin, Italy ; Immunogenetics and Transplantation Biology Unit, 
Azienda Ospedaliera Città della Salute e della Scienza, Ospedale San 
Giovanni Battista, Turin, Italy 
Giribaldi, Giuliana; Department of Oncology, University of Turin Medical 
School, Turin, Italy  
URL: http://mc.manuscriptcentral.com/tbmk  Email: cleo.hall@informa.com
Biomarkers
For Peer Review Only
Destefanis, Paolo; Department of Urology, Azienda Ospedaliera Città della 
Salute e Della Scienza di Torino – Molinette, Turin, Italy 
Keywords: 
Proteomics, Von-Hippel Lindau disease, renal cancer, beta-2-glycoprotein-
1, alpha-1-antitrypsin, urine 
  
 
 
Page 1 of 26
URL: http://mc.manuscriptcentral.com/tbmk  Email: cleo.hall@informa.com
Biomarkers
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
 
1 
Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in Von 
Hippel-Lindau patients 
 
Giorgia Mandili
§a,b
, Agata Notarpietro
§c
, Amina Khadjavi
d
, Marco Allasia
e
, Antonino Battaglia
e
,  
Barbara Lucatello
f
, Bruno Frea
e
, Francesco Turrini
c
, Francesco Novelli
a,b,g
, Giuliana Giribaldi
c
, 
Paolo Destefanis
e
 
 
§ 
These authors equally contributed to the manuscript 
 
a
 Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, 
University of Turin Medical School, Turin, Italy  
b 
Center for Experimental Research and Medical Studies (CeRMS), Città della Salute e della 
Scienza, Ospedale San Giovanni Battista, Turin, Italy  
c  
Department of Oncology, University of Turin Medical School, Turin, Italy  
d 
Department of Surgical Sciences, University of Turin Medical School, Turin, Italy 
e
 Department of Urology, Azienda Ospedaliera Città della Salute e Della Scienza di Torino – 
Molinette, Turin, Italy 
f
 Department of Endocrinology, Diabetology and  Metabolism, Azienda Ospedaliera Città della 
Salute e Della Scienza di Torino –  Molinette, Turin, Italy 
g 
Immunogenetics and Transplantation Biology Unit, Azienda Ospedaliera Città della Salute e della 
Scienza, Ospedale San Giovanni Battista, Turin, Italy 
Page 2 of 26
URL: http://mc.manuscriptcentral.com/tbmk  Email: cleo.hall@informa.com
Biomarkers
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
 
2 
Running head: Markers of renal cancer in VHL syndrome patients 
 
Address all correspondence and requests for reprints to:  
Mandili Giorgia, PhD 
University of Turin Medical School 
Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center 
Via Nizza 52, 10126 - Turin, Italy. 
E-mail: giorgia.mandili@unito.it 
Tel: +39 011 6705850 
Fax: +39 011 6705845  
 
 
 
 
 
Word count: 4956
Page 3 of 26
URL: http://mc.manuscriptcentral.com/tbmk  Email: cleo.hall@informa.com
Biomarkers
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
 
3 
Abstract 
 
CONTEXT Von Hippel-Lindau disease (VHLD) is a rare inherited neoplastic syndrome. Among all 
the VHLD-associated tumors, clear cell renal cell carcinoma (ccRCC) is the major cause of death. 
OBJECTIVE The aim of this paper is the discovery of new non-invasive biomarker for the 
monitoring of VHLD patients. MATERIALS AND METHODS We compared the urinary proteome 
of VHLD patients, ccRCC patients and healthy volunteers. RESULTS Among all differentially 
expressed proteins, A1AT (alpha-1-antitrypsin) and APOH (beta-2-glycoprotein-1) are strongly 
over-abundant only in the urine of VHLD patients with a history of ccRCC. DISCUSSION AND 
CONCLUSION A1AT and APOH could be promising  non-invasive biomarkers. 
 
 
Keywords 
Von-Hippel Lindau disease, renal cancer, beta-2-glycoprotein-1 and alpha-1-antitrypsin, urine, 
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4 
Introduction 
The Von Hippel-Lindau (VHL) disease is a rare autosomal dominant inherited neoplastic syndrome 
(López 2013). The gene responsible for the VHL disease (VHLD) is a tumor suppressor gene 
encoding for a multifunctional protein known for its role as substrate-binding subunit of an E3 
ubiquitin-ligase that, among others, targets the α-subunits of the transcription factors hypoxia-
inducible factors (HIFs-α) for proteasomal degradation. Biallelic inactivation of the VHL gene 
would thereof result in HIF stabilization with subsequent up-regulation of target genes involved in 
angiogenesis, proliferation, apoptosis and metabolism. The VHL gene alteration predisposes to 
several highly vascularized benign and malignant tumors, including retinal and central nervous 
system hemangioblastomas, pheochromocytomas and clear-cell renal cell carcinomas (ccRCCs) 
(Barontini and Dahia 2010; Barrisford et al. 2011; Bader and Hsu 2012). In the last decade, many 
HIF-independent activities have been also described for the VHL protein in many key cellular 
processes, such as regulation of extracellular matrix, senescence, apoptosis, RNA stability, 
endocytosis and gene transcription (Hsu 2012; Richard et al 2013). Among the VHL-associated 
tumors, ccRCC is the major cause of death related to this disease (Maher  et al. 2011). Those VHL-
associated renal carcinomas have histology of the clear cell type and preferentially tend to be 
multifocal, bilateral and cystic (Barontini and Dahia 2010; López 2013). Around two-thirds of the 
patients with VHL germ-line mutations develop early age ccRCC and are at risk of renal cancer 
development of approximately 70% (Lonser et al 2003). Currently, abdominal ultrasound, 
computerized tomography and magnetic resonance imaging allow the monitoring of the patients in 
order to diagnose ccRCC at the earliest stage (Maher et al 2011). Nevertheless, the 
pathophysiological mechanism on the basis of the correlation between kidney cancer and VHLD is 
still unknown. The discovery of a new non-invasive biomarker could be helpful not only to support 
currently used techniques for the clinical monitoring of VHLD patients, but also to obtain a 
better knowledge of the molecular basis of ccRCC onset in VHLD.  
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5 
Since ccRCC usually arises from the epithelial cells of the proximal part of the renal tubule lining 
the urinary tract that contributes to urine formation and given that urine samples can be easily and 
copiously available in a non-invasive manner, we decided to focus on the urinary proteome 
(Bodmer et al. 2002). In order to identify new non-invasive biomarkers, we compared the proteome 
of urine samples provided by healthy volunteers, VHLD-affected subjects and patients with ccRCC. 
Interestingly we identified proteins characteristics of VHLD or sporadic ccRCC, able to 
differentiate them from healthy subjects. In particular, among all the differentially expressed 
proteins, we focus our attention on two proteins that could discriminate between VHLD patients 
with o without ccRCC history, namely A1AT (alpha-1-antitrypsin) and APOH (beta-2-
glycoprotein-1) that could therefore represent promising markers for renal carcinogenesis in VHLD 
patients.  
 
 
Materials and methods 
Population of the Study 
From October 2010 to May 2012 patients with VHLD (with or without ccRCC history) and with 
sporadic ccRCC were enrolled in this study and provided urine specimens. Concomitantly a control 
group composed by 6 male and 2 female healthy volunteers with a mean age of 40.5 years provided 
urine specimens. The protocol was approved by the local research ethical committee and done 
according to Helsinki Declaration principles. All participants in the protocol signed a declaration of 
informed consent. A total of 4 male and 5 female patients with VHLD with a mean SD age of 36.4 
years, 3 male and 6 female patients with ccRCC with a mean SD age of 69.4 years were enrolled. 
Among the 9 VHL patients, 4 experienced at minimum one ccRCC before urine collection (Table 
1). Samples were collected in sterile tubes and processed within 2 hours of sampling.  
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6 
Chemicals and reagents 
Unless otherwise stated, all materials were from Sigma-Aldrich (Milan, Italy). DC Protein assay kit, 
acrylamide, agarose, ready-made immobilized pH gradient (IPG) strip (7- cm IPG strips, pH 3-
10NL) from Bio-Rad (Hercules, CA, USA). Ampholine pH 3.5–10 and horseradish-peroxidase 
labeled antibodies against rabbit or mouse IgG were obtained from GE Healthcare (Milan, Italy). 
The slide-A-lyzer mini dialysis unit plus microtube was purchased from Pierce (Rockford, IL, 
USA). Antibody against APOH was purchased from Abcam (Cambridge, UK). 
Urine Processing 
Urine samples were centrifuged at 700 x g for 20 minutes at 10°C to remove exfoliated urothelial 
cells and debris. Proteins from supernatant were precipitated by acetone 1:1. Pellets were 
solubilized in lysis buffer (urea 9M, CHAPS 4%, Na3VO4 1mM, DTT 80mM, protease inhibitors 
and nuclease). Samples were incubated overnight at 4°C and spun down at 13,800 g for 10 min at 
4°C. The clear supernatant was removed, quantified with DC Protein assay kit and stored at -20°C 
until analysis.  
Two-dimensional gel electrophoresis (2DE) 
200 µg of proteins for each sample were dialyzed against fresh lysis buffer with slide-A-lyzer mini 
dialysis unit plus microtube according to manufacturer’s instructions. 2DE was performed using 
ready-made IPG strip (7-cm IPG strips, pH 3-10NL) and gel stained with Colloidal Coomassie as 
already described (Mandili G et al. 2011). 
Image analysis 
Image analysis for 2DE experiments was performed using PD-Quest software (version 7.2, Bio-
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7 
Rad) according to the manufacturer’s instructions, as previously described (Mandili G et al. 2011).  
Protein identification by mass spectrometry and database search 
Coomassie G-stained spots were excised from 2DE gels; destaining, in-gel enzymatic digestion and 
MALDI-TOF analysis were performed as previously described (Mandili G et al. 2011). The 
following parameters were used in the searches using the free program MASCOT 
(www.matrixscience.com): database SWISSPROT, taxa Homo sapiens, trypsin digest, one missed 
cleavage by trypsin, carbamidomethylation of cysteine as fixed modification, methionine oxidation 
as variable modification and maximum error allowed 100 ppm. Only proteins with a Mascot score 
greater than 56 were considered for further analyses. 
Western blotting 
Lysates containing equal amounts of proteins (10 µg), added with Laemmli buffer (Tris-HCl 60mM 
pH 6.8, SDS 2% w/v, glycerol 10% v/v), were subjected to SDS-PAGE (10% gel). The separated 
proteins were transferred to a nitrocellulose membrane. The blot was probed using antibody against 
APOH or A1AT. Immunoreactivity was detected using an enhanced chemiluminescence kit. 
Densitometric analysis of the bands was performed using free ImageJ software (http://imagej.net). 
Statistical analysis 
Data from image analysis were used as values of protein expression. Two-sided Student’s t test was 
used to evaluate the significance of the variations of protein expression. Statistical significance was 
set at p value ≤ 0.05. For 2DE experiments proteins were classified as differentially expressed if 
ratio in spot intensity was greater than 1.5-fold (protein over-represented) or lower than 0.5- fold 
(protein under-represented). 
The ROC (Receiver Operating Characteristic) curves were computed using GraphPad Prism 6 
Software.  
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8 
Results 
Comparative analysis of 2D gels of urine samples from VHLD patients, healthy subjects and 
ccRCC patients 
To obtain a better insight into renal carcinogenesis in patients with VHLD and identify new 
potential markers for this disease, we investigated the differences in protein profiles between urine 
samples from healthy subjects, VHLD and ccRCC patients. All paired conditions were considered. 
All the differentially expressed proteins identified are listed in Tables 2 and 3 and indicated in 
Figure 1.                                           
Comparative analysis of 2D gels  among  VHLD urine samples  
In the comparison between the 2D maps obtained from urine samples of the two VHLD conditions 
(positive or negative history of ccRCC), image analysis revealed 3 spots differentially expressed 
corresponding to 3 unique proteins: AMY1 (alpha-amylase 1/2B/P), AMYP/2B (pancreatic alpha-
amylase/alpha-amylase 2B) and APOH (beta-2-glycoprotein-1) (Table 3). 
Comparative analysis of 2D gels of VHLD patients and healthy subjects urine samples  
The comparison of 2D maps of urinary proteins from VHLD patients and healthy volunteers 
revealed 7 spots significantly modulated (Table 2) corresponding to ALBU (serum Albumin, 6 
spots) and KNG1 (kininogen1). 
The comparison between the two VHLD subgroups and healthy subjects was also performed. 
Interestingly only 2 spots, both identified as ALBU, were found to be differentially expressed 
between VHLD patients who didn’t experience ccRCC and healthy subjects (Table 3). Indeed, 8 
spots were differentially expressed between VHLD patients who experienced ccRCC and healthy 
subjects: ALBU (3 spots), A1AT (alpha-1-antitrypsin), IGKC (Ig kappa chain C), ITIH4 (inter-
alpha-trypsin inhibitor heavy chain 4, 2 spots) and SEN54 (tRNA splicing endonuclease 
subunit Sen54) (Table 3). 
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9 
All comparisons are visualized in Figure 2. 
Comparative analysis of 2D gels of urine samples from VHLD and ccRCC patients  
In the comparison of 2D maps of urinary proteins from VHLD and ccRCC patients, 17 spots were 
differentially expressed (Table 2) and were referred to 10 proteins: ALBU (3 spots), IGKC (2 
spots), IN80C (INO80 complex subunit C), KCA10 (potassium voltage-gated channel subfamily A 
member 10), SDCB1 (syntenin-1), IGHG1 (3 spots), TRFE (transferrin, 2 spots), AMBP (protein 
AMBP, 2 spots), LIPR3 (pancreatic lipase-related protein 3) and CATD (cathepsin D). The 
comparison between the two VHLD subgroups and the sporadic ccRCC patients was also 
performed. Unexpectedly the urine proteome of VHLD patients who developed renal cancer 
showed a higher number of differences in protein profile than those without renal cancer history 
when compared with the urine of sporadic ccRCC patients: 15 spots corresponding to IGKC, 
IN80C, SDCB1, IGHG1, ITIH4, LAC1/2/3 (Ig lambda-1/2/3 chain C regions), AMBP, SEN54, 
CATD (Table 3). Four of those proteins were also found to be differentially expressed comparing 
the urine of VHLD patients who had not developed cancer with the urine from sporadic ccRCC 
patients: IN80C, IGHG1, LAC1/2/3, AMBP (derived from 5 spots, Table 3).   
All comparisons are visualized in Figure 2. 
Comparative analysis of 2D gels of urine samples from ccRCC patients and healthy subjects  
Eleven spots displayed differential levels in the urine of patients with ccRCC if compared to the 
urine of healthy subjects. They referred to 6 proteins (Table 2): IGHG1 (5spots), IN80C, KCA10, 
SDCB1, AMBP (2 spots) and CATD. All comparisons are visualized in Figure 2. 
APOH and A1AT validation 
Among all the differentially expressed proteins, A1AT and APOH were chosen for western blotting 
validation for their known association with tumors.  
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10 
The western blot in Figure 3a and the histogram in Figure 3b showed the increase of A1AT levels 
in the urine of VHLD patients who had developed renal cancer in comparison to those who did not 
(p= 0.0003) and also to patients with ccRCC (p= 0.0088). 
A similar result was observed analyzing APOH levels. As shown in Figure 3a and in the histogram 
in Figure 3c, APOH levels were considerably higher in the urine of patients who had developed 
renal cancer if compared with the levels in the urine of VHLD patients who had never developed 
cancer (p= 0.012), healthy subjects (p= 0.018) and patients with sporadic ccRCC (p= 0.0005).   
Notably the statistical comparative analysis of the A1AT levels between the two VHLD subgroups, 
performed by the ROC curve analysis (cut-off value=0.34, p=0.014), revealed we were able to 
identify all true negative (5 out of 5 VHL patients with no ccRCC) and all true positive values (4 
out of 4 VHL patients that had developed ccRCC). The same analysis was performed for APOH 
levels (cut-off value=1.79, p = 0.050); it allowed to identify 3 (out of 4) VHLD patients that had 
developed ccRCC, correctly discriminating those patients from the true negative patients (5 out of 5 
detected).  
 
 
Discussion 
Clinical diagnosis routinely relies on urine samples since the collection process is easy and non-
invasive (Gebregiworgis et al. 2016). Since urine is secreted by the kidney through a finely 
controlled urination process, changes in urinary proteome can be generally considered an indication 
of kidney injury (Bodmer et al. 2002). 
The VHLD is a rare neoplastic syndrome caused by germline mutations of the suppressor gene 
VHL.  Despite a wide range of pathological outcomes, ccRCC is the most frequent cause of 
morbidity and mortality among the patients affected by VHLD (López  2013).  
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11 
In order to identify a new useful marker to assess ccRCC risk in VHLD patients and to investigate 
the mechanism of renal carcinogenesis, we performed a proteomic analysis comparing urine 
samples provided by VHLD patients with or without a history of ccRCC, sporadic ccRCC patients 
and healthy subjects. 
The comparison among VHLD patients, ccRCC patients and healthy subjects revealed changes in 
proteins involved in immune system (IGHG1, IGKC, AMBP), cell motility and proliferation 
(CATD), cell permeability (KNG1 and KCA10), lipid metabolism (LIPR3), signal transduction 
(SDCB1), chromatin remodeling (INO80) and ion transport (ALBU, TRFE).  
Among all the identified proteins, alpha-1-antitrypsin (A1AT) and beta-2-glycoprotein 1 (APOH) 
were strongly over-abundant in the urine of VHLD patients with history of ccRCC in comparison to 
the urine of all the other conditions.   
A1AT is a protease inhibitor that protects tissues from the inflammatory cells proteases. A huge 
increase in A1AT urinary excretion was described in a model of acute kidney injury (Zager et al. 
2014) and in patients affected by renovascular hypertension, probably because of local changes in 
the kidney (Lisowska-Myjak 2005). Furthermore, high A1AT levels have also been described in 
association with tumors (bladder cancer (Miyake et al. 2013), colorectal cancer (Pérez-Holanda et 
al. 2014), cervical cancer (Boichenko et al. 2014) and lung cancer (Liang et al. 2015)), suggesting 
its involvement in tumor development even though its role has not yet been understood. We can 
hypothesize that local structural changes occurring in the kidney following VHLD-induced ccRCC 
could cause increased excretion of A1AT in the urine of VHLD patients with ccRCC history, 
leading to the high level observed in the present study. Impressively, increased A1AT levels were 
also described in another lesser common benign lesion that may occur as a manifestation of VHLD, 
the papillary cystadenoma of the epididymis (Gilcrease et al. 1995), suggesting a direct link 
between A1AT overexpression and VHL mutation.   
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12 
APOH is a multifunctional protein belonging to the apolipoprotein family. It mainly prevents the 
activation of the intrinsic blood coagulation cascade by binding to phospholipids on the surface of 
damaged cells. A role for APOH in the modulation of angiogenesis has also been described 
(Passam et al. 2010) and this could explain its relationship with the onset of ccRCC, a highly 
vascularizated tumor, and VHLD. According to our results, APOH was previously identified as one 
of the major urinary proteins over-excreted by patients with several renal tubular diseases (Norden 
et al. 1991). Moreover, APOH levels were already reported to reflect tumor progression in several 
cancers, including acute myeloid leukemia (Lee et al. 2012), breast cancer (Chung et al. 2014), non-
small lung cancer (Pietrowska et al. 2014) and hepatocellular carcinoma (Jing et al 2010).  
Interestingly we also identified 6 proteins which differentiated urine of sporadic ccRCC patients 
from those of healthy subjects. The discovery of new ccRCC biomarkers is still an open field and 
although ultrasonography represents a major tool for diagnosis and screening of renal masses, not 
invasive biomarkers could became helpful complementary research methods in diagnosis and 
prognosis (Giribaldi et al. 2013). Obviously  validation of these proteins as possible markers will be 
necessary, but our observations could represent the bases of future studies.  
In conclusion, our results suggest A1AT and APOH as promising markers for ccRCC in VHLD 
patients. A1AT and APOH levels in urine might contribute to identify patients who are more 
susceptible to develop cancer, allowing a better follow-up of VHLD patients.  
Because of the extremely rarity of this pathology, our work, even with only 9 VHLD patients, could 
represent an important contribution in the VHLD study, even though further analysis on a larger 
cohort of patients will be necessary to fully validate our observations and deeply elucidate the role 
of A1AT and APOH in carcinogenesis. With a future perspective study will be possible the 
evaluation of diagnostic and prognostic power of this two markers and their correlation with factors 
such as sex, age, smoking, BMI, hypertension and for cases, tumor grade, stage and size.   
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Moreover our discovery of the involvement of A1AT and APOH in the carcinogenesis of ccRCC 
opens new scenarios for the study of this tumor even in the perspective of the development of new 
targeted therapies.  
 
 
 
Geolocalization data 
Italy, Piemonte, Turin. Latitude 45.05. Longitude 7.6667 
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Table 1. Patients characteristics   
Pts 
date of 
birth 
gender 
date of 
urine 
collection 
familiarity RCC 
others VHL-related 
pathologies 
mutation 
VHL1 22/06/78 F 01/12/2011 no no 
central nervous system and 
retinal hemangioblastomas, 
bilateral 
pheochromocytomas, 
pancreatic cysts sx  
R161Q (CGA-CAA) 
exon 3  
VHL2 19/06/67 F 01/12/2011 yes (mother) pT1a Gx 
central nervous system and 
retinal hemangioblastomas, 
pancreatic cysts 
_ 
VHL3 21/10/87 M 07/12/2011 no 
no  (october 2014: 
pT1aG1) 
central nervous system and 
retinal hemangioblastomas, 
bilateral 
pheochromocytomas, 
multiple pancreatic cysts  
499C>T (p.Arg167Trp) 
phenotype 2B  
VHL5 19/09/84 M 08/05/2012 
yes (father, 
brother) 
pT1aGx 
pancreatic cysts, retinal 
angioma 
_ 
VHL6 24/11/73 M 08/05/2012 
yes (father, 
brother) 
pT1aGx 
central nervous system and 
retinal hemangioblastomas, 
pancreatic and renal cysts 
_ 
VHL8 05/05/83 F 08/05/2012 no 
no (january 2014: 
pT1aGx) 
central nervous system and 
retinal hemangioblastomas, 
pancreatic and renal cysts 
N78S 
VHL9 16/11/88 F 08/05/2012 yes (father) no 
retinal hemangioblastomas, 
pancreatic and renal 
cysts, endolymphatic sac 
tumors  
Deletion exon 1  
VHL10 24/09/84 M 08/05/2012 
yes (mother, 
brother) 
no 
bilateral 
pheochromocytomas 
heterozigous missense 
467A>C (p. Y156S) in 
exon 3  
VHL11 04/08/54 F 08/05/2012 yes (two sons) pT1aG2 
retinal 
hemangioblastomas, bilater
al pheochromocytomas, 
pancreatic neuroendocrine 
tumours 
heterozigous missense 
467A>C (p. Y156S) in 
exon 3  
R1 17/05/55 F 18/10/2010 _ pT2bG3 _ _ 
R4 27/02/67 F 28/10/2010 _ pT3aG2 _ _ 
R5 28/01/35 F 03/11/2010 _ pT1bNo _ _ 
R9 27/04/62 M 28/04/2011 _ pT2aG3 _ _ 
R11 26/09/32 F 05/07/2011 _ pT3aG2 _ _ 
R12 31/08/37 M 23/11/2011 _ pT3aG4 _ _ 
R13 04/04/52 M 21/12/2011 _ pT3aG2N0 _ _ 
R17 15/02/37 F 25/01/2012 _ pT3aNx _ _ 
R21 
19/093/19
33 
F 12/03/2012 _ pT2aG2 
_ _ 
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Table 2. Identified proteins in VHLD patients, ccRCC patients and healthy subjects’ urine 
Acronym (ID), Swissprot accession number, name, molecular weight (MW), isoelectric point (pI), 
Spot number according to spot position in 2DE in Figure1, Mascot score, sequence coverage 
(percentage of identified sequence of the matched protein) and number of matched peptides out of 
25 are indicated 
Proteins differentially expressed in urine of VHLD patients vs healthy subjects 
ID 
Accession 
Number 
Name MW pI Nr spot 
Mascot 
Score 
Coverage % 
Matched 
peptides 
ALBU P02768 Serum 
albumin 
71317 5,92 
606 222 36 19 
705 175 24 14 
2603 245 33 21 
3704 292 39 22 
3803 243 38 20 
4804 254 36 20 
KNG1 P01042 Kininogen-1 72996 6,34 705 175 22 11 
Proteins differentially expressed in urine of  VHLD patients vs ccRCC patients 
ID 
Accession 
Number 
Name MW pI Nr spot 
Mascot 
Score 
Coverage % 
Matched 
peptides 
ALBU P02768 Serum 
albumin 
71317 5,92 
2603 245 33 21 
4702 124 23 11 
4804 254 36 20 
IGKC P01834 Ig kappa chain C region 11773 5,58 
3301 68 66 4 
8201 68 66 4 
IN80C Q6PI98 
INO80 
complex 
subunit C 
20630 10,03 3401 57 30 4 
KCA10 Q16322 
Potassium 
voltage-gated 
channel 
subfamily A 
member 10 
58147 4,85 3601 61 18 6 
SDCB1 O00560 Syntenin-1 32595 7,05 9501 74 31 5 
IGHG1 P01857 
Ig gamma-1 
chain C region 
36596 8,46 
9501 74 25 5 
9704 84 36 7 
9705 77 35 7 
TRFE P02787 Serotransferrin 79294 6,81 9912 209 28 19 
9913 183 29 18 
AMBP P02760 Protein AMBP 39886 5,95 9932 61 23 7 
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20 
9951 59 22 6 
LIPR3 Q17RR3 
Pancreatic 
lipase-related 
protein 3   
  9952 57     
CATD P07339 Cathepsin D 45037 6,1 9958 84 25 8 
Proteins differentially expressed in urine of ccRCC patients  vs healthy subjects 
ID 
Accession 
Number 
Name MW pI Nr spot 
Mascot 
Score 
Coverage % 
Matched 
peptides 
IN80C Q6PI98 
INO80 
complex 
subunit C 
20630 10,03 3401 57 30 4 
KCA10 Q16322 
Potassium 
voltage-gated 
channel 
subfamily A 
member 10 
58147 4,85 3601 61 18 6 
SDCB1 O00560 Syntenin-1 32595 7,05 9501 74 31 5 
IGHG1 P01857 
Ig gamma-1 
chain C region 
36596 8,46 
9501 74 25 5 
9704 84 36 7 
9705 77 35 7 
9706 93 36 7 
9935 82 36 8 
AMBP P02760 Protein AMBP 39886 5,95 9932 61 23 7 
9951 59 22 6 
CATD P07339 Cathepsin D 45037 6,1 9958 84 25 8 
 
 
 
 
 
 
Table 3. Identified proteins in VHLD patients with or without ccRCC history, ccRCC patients 
and healthy subjects’ urine 
Acronym (ID), Swissprot accession number, name, molecular weight (MW), isoelectric point (pI), 
Spot number according to spot position in 2DE in Figure1, Mascot score, sequence coverage 
(percentage of identified sequence of the matched protein) and number of matched 
peptides out of 25 are indicated 
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21 
Proteins differentially expressed in urine of VHLD patients with ccRCC history vs healthy subjects 
ID 
Accession 
Number 
Name MW pI Nr spot 
Mascot 
Score 
Coverage % 
Matched 
peptides 
ALBU P02768 Serum 
albumin 
71317 5,92 
606 222 36 19 
2603 245 33 21 
3704 292 39 22 
A1AT P01009 Alpha-1-antitrypsin 46878 5,37 707 129 33 11 
IGKC P01834 Ig kappa chain C 11773 5,58 9929 63 
66 
4 
ITIH4 Q14624 
Inter-alpha-
trypsin 
inhibitor 
heavy chain 
H4  
103521 6,51 
9919 78 17 10 
9921 60 13 6 
SEN54 Q7Z6J9 
tRNA-splicing 
endonuclease 
subunit 
Sen54 
59296 8,03 9946 57 12 6 
Proteins differentially expressed in urine of VHLD patients without ccRCC history vs healthy subjects 
ID 
Accession 
Number 
Name MW pI Nr spot 
Mascot 
Score 
Coverage % 
Matched 
peptides 
ALBU P02768 Serum 
albumin 
71317 5,92 
606 222 36 19 
2603 245 33 21 
Proteins differentially expressed in urine of  VHLD patients with ccRCC history vs VHLD patients 
without ccRCC history 
ID 
Accession 
Number 
Name MW pI Nr spot 
Mascot 
Score 
Coverage % 
Matched 
peptides 
AMY1 P04745 
Alpha-
amylase 
1/2B/P 
58415 6.47 8701 179 33 12 
AMYP/2B P04746/ P19961 
Pancreatic 
alpha-
amylase/ 
Alpha-
amylase 2B 
58354/ 58300 6,60/ 6,64 8702 57 17 7 
APOH P02749 Beta-2-glycoprotein 1 39584 8.34 8701 179 33 7 
Proteins differentially expressed in urine of VHLD patients with ccRCC history vs ccRCC patients 
ID 
Accession 
Number 
Name MW pI Nr spot 
Mascot 
Score 
Coverage % 
Matched 
peptides 
IGKC P01834 
Ig kappa 
chain C 
region 
11773 5,58 
3301 68 66 4 
9929 63 
66 
4 
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IN80C Q6PI98 
INO80 
complex 
subunit C 
20630 10,03 3401 57 30 4 
SDCB1 O00560 Syntenin-1 32595 7,05 9501 74 31 5 
IGHG1 P01857 
Ig gamma-1 
chain C 
region 
36596 8,46 
9501 74 25 5 
9704 84 36 7 
9935 82 36 8 
ITIH4 Q14624 
Inter-alpha-
trypsin 
inhibitor 
heavy chain 
H4  
103521 6,51 
9919 78 17 10 
9921 60 13 6 
LAC1/2/3 P0CG04/5/6  
Ig lambda-
1/2/3 chain C 
regions 
11512/ 
11458/ 11402 7,89/ 6,92/ 
6,92  
9931 63 65 4 
AMBP P02760 Protein AMBP 39886 5,95 9932 61 23 7 
9951 59 22 6 
SEN54 Q7Z6J9 
tRNA-splicing 
endonuclease 
subunit 
Sen54 
59296 8,03 9946 57 12 6 
CATD P07339 Cathepsin D 45037 6,1 9958 84 25 8 
Proteins differentially expressed in urine of VLHD patients without ccRCC history vs ccRCC patients 
ID 
Accession 
Number 
Name MW pI Nr spot 
Mascot 
Score 
Coverage % 
Matched 
peptides 
IN80C Q6PI98 
INO80 
complex 
subunit C 
20630 10,03 3401 57 30 4 
IGHG1 P01857 
Ig gamma-1 
chain C 
region 
36596 8,46 9705 77 35 7 
LAC1/2/3 P0CG04/5/6  
Ig lambda-
1/2/3 chain C 
regions 
11512/ 
11458/ 11402 7,89/ 6,92/ 
6,92  
9931 63 65 4 
AMBP P02760 Protein AMBP 39886 5,95 9932 61 23 7 
9951 59 22 6 
 
Legends to figures 
Figure 1. Representative 2DE map of urinary proteins 
 The spots corresponding to all the identified proteins differentially expressed among the analyzed 
clinical conditions are indicated on the figure by arrows and listed in Tables 2 and 3. 
Figure 2. Modulated proteins in VHLD in comparison to other conditions 
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23 
a) Venn diagram highlighting proteins modulated in the comparison among VHLD patients, ccRCC 
patients and healthy subjects. b) Venn diagram highlighting proteins modulated in the comparison 
among VHLD patients with (VHL K) or without (VHL no K) ccRCC history, ccRCC patients and 
healthy subjects 
Figure 3. A1AT and APOH validation  
a) Representative western blotting images of A1AT and APOH in urine provided by healthy 
volunteers (C1 and C2), VHLD patients without ccRCC history (VHL no k, V1), VHLD patients 
with ccRCC history (VHL k, V2) and patients with sporadic renal cancer (R1 and R2). b) and c) 
show the corresponding distribution of the data obtained from the densitometric analysis of A1AT 
and APOH expression respectively ( * p<0.05; ** p<0.01; *** p<0.005). 
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